Results 161 to 170 of about 687,018 (362)

Embedded 3D‐Coaxial Bioprinting of Stenotic Brain Vessels with a Mechanically Enhanced Extracellular Matrix Bioink for Investigating Hemodynamic Force‐Induced Endothelial Responses

Advanced Functional Materials, EarlyView.
In this study, a physically enhanced vascular dECM bioink and used 3D‐coaxial bioprinting are developed to fabricate mature brain blood vessels for cerebral atherosclerosis research. This model demonstrates that vascular geometry‐induced hemodynamic changes trigger vascular inflammation, ensuring its potential for cerebrovascular research.
Wonbin Park, Min‐Ju Choi, Jae‐Seong Lee, Minjun Ahn, Wonil Han, Ge Gao, Dong‐Woo Cho, Byoung Soo Kim   +7 more
wiley   +1 more source

U.S. Food and Drug Administration Approval of AmBisome (Liposomal Amphotericin B) for Treatment of Visceral Leishmaniasis

, 1999
Andrea Meyerhoff
openalex   +1 more source

Soluble fiber intake at a dose approved by the US Food and Drug Administration for a claim of health benefits: serum lipid risk factors for cardiovascular disease assessed in a randomized controlled crossover trial [PDF]

, 2002
David J.A. Jenkins, Cyril W.C. Kendall, Vladimir Vuksan, Edward Vidgen, Tina Parker, Dorothea Faulkner, Christine C. Mehling, Marcella Garsetti, G. Testolin, Stephen C. Cunnane, Mary Ann Ryan, Paul Corey   +11 more
openalex   +1 more source

Transforming Cellulose Into Functional Three‐Dimensional Structures

Advanced Functional Materials, EarlyView.
Cellulose is promising for replacing synthetic polymers due to its excellent mechanical properties and low cost. This review highlights the recent advancements in transforming cellulose into functional 3D structures, including liquid gels and porous materials.
Xia Sun, Hao Sun, Penghui Zhu, Yonggang Wu, Anna Palmer, Feng Jiang   +5 more
wiley   +1 more source

Reform proposal for Food and Drug Administration

, 1995
Alicia Ault Barnett
openalex   +1 more source

Concomitant Risk Factors in Reports of Torsades de Pointes Associated with Macrolide Use: Review of the United States Food and Drug Administration Adverse Event Reporting System [PDF]

, 2002
Douglas Shaffer, Sarah Singer, Joyce A. Korvick, Peter K. Honig   +3 more
openalex   +1 more source

Endocytic Programming via Porous Silicon Nanoparticles Enhances TLR4 Nanoagonist Potency for Macrophage‐Mediated Immunotherapy

Advanced Functional Materials, EarlyView.
Porous silicon nanoparticles (PSiNPs) reprogram macrophage endocytosis of manganese@albumin‐based TLR4 nanoagonists, driving TRIF‐biased TLR4 signaling, eliciting robust proinflammatory responses, and potentiating macrophage‐mediated immunotherapeutic effects against NSCLC.
Xiaomei Zhang, Huiying Li, Shuodan Huang, Linxuan Zhang, Yan Gao, Ruoran Wang, Xiaoyu Wang, Hélder A. Santos, Zhenyu Yin, Bing Xia   +9 more
wiley   +1 more source

Hardly a Windfall: Prescribing Practices in Pediatric Heart Failure Around Food and Drug Administration Approval. [PDF]

JACC Adv
Ludomirsky AB, Edelson JB, Lin KY, Berger JH, O'Connor MJ, Wittlieb-Weber CA, Griffis H, Zhang B, Rossano JW.   +8 more
europepmc   +1 more source

Urokinase and the US Food and Drug Administration [PDF]

Journal of Vascular Surgery, 1999
openaire   +3 more sources

A Short Course on the Food and Drug Administration: What You Should Know [PDF]

, 2002
Jean L. Fourcroy
openalex   +1 more source